Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases

Research output: Contribution to journalReviewResearchpeer-review

  1. Checkpoint inhibitors in pancreatic cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Checkpoint inhibitors in breast cancer - Current status

    Research output: Contribution to journalReviewResearchpeer-review

  4. A systematic review of bevacizumab efficacy in breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Symptomer fra mundhulen

    Research output: Chapter in Book/Report/Conference proceedingCompendium/lecture notes chapterEducationpeer-review

  3. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment

    Research output: Contribution to journalReviewResearchpeer-review

  4. Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment. While the implementation of preventive measures over recent years has reduced the risk of MRONJ in patients with bone metastases due to cancer, it is imperative to balance the risk of MRONJ against the beneficial effects of treatment with denosumab or bisphosphonates on the skeletal health of patients. Despite growing awareness of MRONJ within the medical community, there is a lack of large-scale, prospective clinical studies in this rapidly evolving field. Discussing preventive measures with patients and implementing them, both before and during treatment with bisphosphonates or denosumab, is the best option to reduce the risk of MRONJ. In particular, avoiding bone trauma and preventing and treating dental infections before and during denosumab or bisphosphonate therapy is crucial to minimize the risk of MRONJ. If MRONJ develops, conservative (non-surgical) treatment can provide symptom relief, but achieving mucosal closure remains challenging. When management of symptoms and mucosal healing are the ultimate goals of therapy, or after failure of conservative treatment, a surgical approach may be beneficial. This critical review, based on a best-evidence review of currently available literature, provides clear practical guidelines to help to prevent, manage and treat MRONJ. Overall, a multidisciplinary, pragmatic approach to MRONJ should be adopted, prioritizing patient's quality of life and management of their skeletal malignant disease.

Original languageEnglish
JournalCancer Treatment Reviews
Volume69
Pages (from-to)177-187
Number of pages11
ISSN0305-7372
DOIs
Publication statusPublished - Sep 2018

    Research areas

  • Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnosis, Bone Density Conservation Agents/adverse effects, Bone Neoplasms/drug therapy, Diphosphonates/adverse effects, Humans, Neoplasms/drug therapy, Quality of Life, Risk Factors

ID: 56437468